PIK3CD and glioblastoma: Our previous study showed that combination of the selective PI3K p110β isoform (PI3Kβ) inhibitor (TGX-221) and the JNK inhibitor (SP600125) displayed moderate synergistic inhibitory effects on in-vitro GBM cell proliferation, migration and in-vivo xenograft growth [10].